JY
AVXL icon

Jeff Yass’s Anavex Life Sciences AVXL Stock Holding History

Jeff Yass’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$828K Sell
319,529
-676,134
-68% -$2M ﹤0.01% 8692
2026
Q1 		$3.06M Buy
995,663
+556,164
+127% +$2.41M ﹤0.01% 5235
2025
Q4 		$1.56M Sell
439,499
-164,319
-27% -$1.01M ﹤0.01% 6148
2025
Q3 		$5.37M Sell
603,818
-2,849
-0.5% -$28.9K ﹤0.01% 3966
2025
Q2 		$5.59M Sell
606,667
-180,433
-23% -$1.54M ﹤0.01% 3767
2025
Q1 		$6.75M Sell
787,100
-347,638
-31% -$3.28M ﹤0.01% 3108
2024
Q4 		$12.2M Buy
1,134,738
+896,321
+376% +$6.89M ﹤0.01% 2416
2024
Q3 		$1.35M Sell
238,417
-26,018
-10% -$150K ﹤0.01% 6145
2024
Q2 		$1.12M Sell
264,435
-37,625
-12% -$152K ﹤0.01% 6325
2024
Q1 		$1.54M Sell
302,060
-419,293
-58% -$2.36M ﹤0.01% 5943
2023
Q4 		$6.72M Buy
721,353
+275,440
+62% +$1.9M ﹤0.01% 3227
2023
Q3 		$2.92M Sell
445,913
-187,726
-30% -$1.49M ﹤0.01% 4431
2023
Q2 		$5.15M Buy
633,639
+24,845
+4% +$213K ﹤0.01% 3478
2023
Q1 		$5.22M Buy
608,794
+233,906
+62% +$2.33M ﹤0.01% 3408
2022
Q4 		$3.47M Buy
374,888
+12,571
+3% +$134K ﹤0.01% 3790
2022
Q3 		$3.74M Buy
362,317
+81,160
+29% +$857K ﹤0.01% 3652
2022
Q2 		$2.81M Buy
281,157
+859
+0.3% +$8.14K ﹤0.01% 4202
2022
Q1 		$3.45M Sell
280,298
-263,725
-48% -$3.24M ﹤0.01% 4355
2021
Q4 		$9.43M Buy
544,023
+51,840
+11% +$985K ﹤0.01% 2807
2021
Q3 		$8.84M Sell
492,183
-193,833
-28% -$3.86M ﹤0.01% 3048
2021
Q2 		$15.7M Buy
686,016
+655,260
+2,131% +$9.71M ﹤0.01% 2322
2021
Q1 		$460K Sell
30,756
-110,825
-78% -$1.21M ﹤0.01% 9674
2020
Q4 		$765K Sell
141,581
-163,352
-54% -$861K ﹤0.01% 7319
2020
Q3 		$1.39M Buy
304,933
+87,229
+40% +$375K ﹤0.01% 5342
2020
Q2 		$1.07M Sell
217,704
-25,148
-10% -$95K ﹤0.01% 5765
2020
Q1 		$765K Buy
242,852
+98,325
+68% +$343K ﹤0.01% 5983
2019
Q4 		$374K Sell
144,527
-12,514
-8% -$32.8K ﹤0.01% 7560
2019
Q3 		$496K Sell
157,041
-81,517
-34% -$235K ﹤0.01% 7326
2019
Q2 		$803K Sell
238,558
-98,967
-29% -$307K ﹤0.01% 6182
2019
Q1 		$1.03M Buy
337,525
+212,588
+170% +$508K ﹤0.01% 4994
2018
Q4 		$195K Sell
124,937
-79,062
-39% -$179K ﹤0.01% 7773
2018
Q3 		$557K Buy
203,999
+27,339
+15% +$77.1K ﹤0.01% 6317
2018
Q2 		$463K Buy
176,660
+102,177
+137% +$285K ﹤0.01% 6942
2018
Q1 		$206K Sell
74,483
-189,884
-72% -$537K ﹤0.01% 8276
2017
Q4 		$851K Buy
264,367
+27,872
+12% +$110K ﹤0.01% 5557
2017
Q3 		$979K Sell
236,495
-28,536
-11% -$127K ﹤0.01% 5309
2017
Q2 		$1.41M Sell
265,031
-8,881
-3% -$51.3K ﹤0.01% 4550
2017
Q1 		$1.57M Sell
273,912
-56,557
-17% -$292K ﹤0.01% 4174
2016
Q4 		$1.31M Buy
330,469
+207,327
+168% +$739K ﹤0.01% 4961
2016
Q3 		$447K Buy
123,142
+102,685
+502% +$432K ﹤0.01% 6280
2016
Q2 		$125K Sell
20,457
-116,798
-85% -$564K ﹤0.01% 7914
2016
Q1 		$673K Buy
137,255
+39,537
+40% +$174K ﹤0.01% 5871
2015
Q4 		$544K Buy
+97,718
New +$695K ﹤0.01% 6594

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's AVXL Position: Q2 2026 in Review

Jeff Yass reduced its Anavex Life Sciences (AVXL) stake by 68% in Q2 2026, selling an estimated $2M and leaving 319,529 shares worth $828K. The position accounts for ﹤0.01% of the portfolio, ranked #8692.

Jeff Yass first reported a position in AVXL in Q4 2015 and has held it in 43 quarters since. The position peaked at $15.7M in Q2 2021. 177 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Jeff Yass held 319,529 shares of Anavex Life Sciences worth $828K as of Q2 2026.
  • Jeff Yass sold 676,134 Anavex Life Sciences shares in Q2 2026, an estimated $2M.
  • Anavex Life Sciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8692 holding.
  • Jeff Yass first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 43 quarters since.
  • Jeff Yass's Anavex Life Sciences position peaked at $15.7M in Q2 2021.
  • 177 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.